Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer

(2021) Anqi Lin et al.   Frontiers in Immunology

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas

(2021) Zhiyong Liu et al.   Cancer Management and Research

Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review

(2021) Yanna Lei et al.   Frontiers in Immunology

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma

(2020) Hai-ying Wang et al.   OncoTargets and Therapy

Safety, Efficacy and Biomarker Analysis of Toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial

(2020) Bixia Tang et al.   CLINICAL CANCER RESEARCH

Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study

(2020) Jianliang Yang et al.   EUROPEAN JOURNAL OF CANCER

Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report

(2020) Shalabh Arora et al.   Clinical Sarcoma Research

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

(2019) Yongshuai Jiang et al.   Human Vaccines & Immunotherapeutics

Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer

(2019) Sandra Assoun et al.   LUNG CANCER

PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition

(2019) Cretella et al.   Cancers

Early detection and integral resection are keys to extend survival in patients suffered from primary angiosarcoma of the spleen

(2018) Xuchun Chen et al.   MEDICINE

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

(2018) Hongshu Sui et al.   Journal of Immunology Research

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma

(2017) Gerardo Botti et al.   Journal of Cancer

Littoral cell angioma of the spleen: a study of 25 cases with confirmation of frequent association with visceral malignancies

(2016) Kvetoslava Peckova et al.   HISTOPATHOLOGY

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

(2015) Kathleen M. Mahoney et al.   CLINICAL THERAPEUTICS

Vascular-targeted agents for the treatment of angiosarcoma

(2013) R. J. Young et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

(2013) Y. Huang et al.   CANCER RESEARCH